GC376

GC376
Legal status
Legal status	US: Investigational drug;
Identifiers
	IUPAC name sodium (2S)-1-hydroxy-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate;
CAS Number	1416992-39-6 ;
PubChem CID	71481119;
ChemSpider	29396096;
UNII	H1NMJ5XDG5;
ChEMBL	ChEMBL2315036;
Chemical and physical data
Formula	C21H30N3NaO8S
Molar mass	507.53 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C[C@@H](C(=O)N[C@@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2=CC=CC=C2.[Na+];
	InChI InChI=1S/C21H31N3O8S.Na/c1-13(2)10-16(24-21(28)32-12-14-6-4-3-5-7-14)19(26)23-17(20(27)33(29,30)31)11-15-8-9-22-18(15)25;/h3-7,13,15-17,20,27H,8-12H2,1-2H3,(H,22,25)(H,23,26)(H,24,28)(H,29,30,31);/q;+1/p-1/t15?,16-,17-,20?;/m0./s1; Key:BSPJDKCMFIPBAW-JPBGFCRCSA-M;

GC376 is a broad-spectrum antiviral medication under development by the biopharmaceutical company Anivive Lifesciences for therapeutic uses in humans and animals.^[1] Anivive licensed the exclusive worldwide patent rights to GC376 from Kansas State University.^[2] As of 2020, GC376 is being investigated as a treatment for COVID-19.^[3] GC376 shows activity against many human and animal viruses, including coronavirus and norovirus;^[4] the most extensive research has been multiple in vivo studies in cats treating a coronavirus, which causes deadly feline infectious peritonitis.^[5] Other research supports use in porcine epidemic diarrhea virus.^[6]

^ "Anivive". www.anivive.com. Retrieved 2020-05-14.
^ "Anivive licenses antiviral drug for fatal cat disease". www.k-state.edu. September 20, 2018. Retrieved 2020-05-14.
^ Stockwell B (6 May 2020). "COVID-19 Virtual Symposium". Retrieved 2020-05-14 – via YouTube.
^ Takahashi D, Kim Y, Lovell S, Prakash O, Groutas WC, Chang KO (December 2013). "Structural and inhibitor studies of norovirus 3C-like proteases". Virus Research. 178 (2): 437–444. doi:10.1016/j.virusres.2013.09.008. PMC 3840063. PMID 24055466.
^ Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, et al. (April 2018). "Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis". Journal of Feline Medicine and Surgery. 20 (4): 378–392. doi:10.1177/1098612X17729626. PMC 5871025. PMID 28901812.
^ Ye G, Wang X, Tong X, Shi Y, Fu ZF, Peng G (February 2020). "Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376". Viruses. 12 (2): 240. doi:10.3390/v12020240. PMC 7077318. PMID 32098094.

[1] "Anivive". www.anivive.com. Retrieved 2020-05-14.

[2] "Anivive licenses antiviral drug for fatal cat disease". www.k-state.edu. September 20, 2018. Retrieved 2020-05-14.

[Stockwell_2020-3] Stockwell B (6 May 2020). "COVID-19 Virtual Symposium". Retrieved 2020-05-14 – via YouTube.

[4] Takahashi D, Kim Y, Lovell S, Prakash O, Groutas WC, Chang KO (December 2013). "Structural and inhibitor studies of norovirus 3C-like proteases". Virus Research. 178 (2): 437–444. doi:10.1016/j.virusres.2013.09.008. PMC 3840063. PMID 24055466.

[5] Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, et al. (April 2018). "Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis". Journal of Feline Medicine and Surgery. 20 (4): 378–392. doi:10.1177/1098612X17729626. PMC 5871025. PMID 28901812.

[PEDV-6] Ye G, Wang X, Tong X, Shi Y, Fu ZF, Peng G (February 2020). "Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376". Viruses. 12 (2): 240. doi:10.3390/v12020240. PMC 7077318. PMID 32098094.

[1]

[2]

[3]

[4]

[5]

[6]